Salmonella typhi ty2 vi polysaccharide antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Salmonella typhi ty2 vi polysaccharide antigen
Accession Number
DB10803
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated / Other vaccines
Description

Salmonella typhi ty2 vi polysaccharide antigen is a vaccine that is administered intramuscularly. It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. The vaccine contains the purified cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain. The bacterial culture is inactivated in the medium with the capsular polysaccharides precipated from the solution.

Synonyms
  • Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Typhim ViInjection, solution25 ug/0.5mLIntramuscularA-S Medication Solutions1994-11-28Not applicableUs
Typhim ViInjection, solution25 ug/0.5mLIntramuscularSanofi Pasteur Inc.1994-11-28Not applicableUs
Typhim ViInjection, solution25 ug/0.5mLIntramuscularA-S Medication Solutions1994-11-28Not applicableUs
Typhim ViSolution25 mcgIntramuscularSanofi Pasteur Limited1995-12-31Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
VivaximSalmonella typhi ty2 vi polysaccharide antigen (25 mcg) + Hepatitis A Vaccine (160 unit)Solution; SuspensionIntramuscularSanofi Pasteur Limited2005-11-09Not applicableCanada
Categories
UNII
7194H8W3KT
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with 2-Methoxyethanol.
6-Deoxyerythronolide BThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Abetimus.
Acetyl sulfisoxazoleThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Acetyl sulfisoxazole.
ActeosideThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Afelimomab.
AldesleukinThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Aldesleukin.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910909
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceCardiovascular Function1
0CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedPreventionSalmonella Typhi Infection1
1CompletedTreatmentAcute Coronary Syndromes (ACS) / Inflammatory Reaction / Myocardial Infarction / Reperfusion Injury1
1RecruitingPreventionCardiovascular Disease (CVD)1
2Active Not RecruitingPreventionSalmonella Typhi Infection1
2CompletedPreventionDengue Diseases / Dengue Fever / Dengue Hemorrhagic Fever / Dengue Virus1
3CompletedPreventionBacterial Infections / Salmonella Infections / Salmonella Typhi Infection1
4Enrolling by InvitationBasic ScienceFlu caused by Influenza / Healthy Adults / Hepatitis A / Salmonella Typhi Infection1
4RecruitingDiagnosticSpecific Polysaccharide Antibody Deficiency1
Not AvailableCompletedBasic ScienceBCG Vaccination1
Not AvailableCompletedBasic ScienceTyphoid Vaccine on Sleep1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular25 ug/0.5mL
SolutionIntramuscular25 mcg
Solution; suspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on January 22, 2019 17:57